bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary methods from Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Authors: Dorywalska Magdalena , Dushin Russell , Moine Ludivine , Farias Santiago E. , Zhou Dahui , Navaratnam Thayalan , Lui Victor , Hasa-Moreno Adela , Casas Meritxell Galindo , Tran Thomas-Toan , Delaria Kathy , Liu Shu-Hui , Foletti Davide , O'Donnell Christopher J. , Pons Jaume , Shelton David L. , Rajpal Arvind , Strop Pavel
Published: April 2023

Experimental Procedures for the Preparation of Linker-Payloads.
Table S3. Increased trametinib and selumetinib sensitivity when DasRes cell lines are maintained in 2μM dasatinib. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

A.) IC50 values were calculated using the PRISM software and non-variable slope analysis. Fold increase in sensitivity was calculated based on changes IC50 values in the DasRes + 2μM dasatinib in relation to the DasRes cell line IC50 values.
Supplementary Matierial from Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions
Authors: Kashyap Abhishek S. , Shooter Gary K. , Shokoohmand Ali , McGovern Jacqui , Sivaramakrishnan Manaswini , Croll Tristan I. , Cane Gaëlle , Leavesley David I. , Söderberg Ola , Upton Zee , Hollier Brett G.
Published: April 2023

Supplementary materials and methods
Table S1. Analysis of relative dasatinib resistance. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

IC50 values were calculated using the PRISM software and non-variable slope. Fold change relative to control IC50 values are depicted as relative resistance.
Supplemental Methods from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

Methods section for supplemental data
Legends to supplementary figures from Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Authors: Boukalova Stepana , Stursa Jan , Werner Lukas , Ezrova Zuzana , Cerny Jiri , Bezawork-Geleta Ayenachew , Pecinova Alena , Dong Lanfeng , Drahota Zdenek , Neuzil Jiri
Published: April 2023

This file contains legends to supplementary figures
Supplementary Figure 1 from Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts
Authors: Mohamed Suhaimi Nur-Afidah , Phyo Wai Min , Yap Hao Yun , Choy Sharon Heng Yee , Wei Xiaona , Choudhury Yukti , Tan Wai Jin , Tan Luke Anthony Peng Yee , Foo Roger Sik Yin , Tan Suzanne Hui San , Tiang Zenia , Wong Chin Fong , Koh Poh Koon , Tan Min-Han
Published: April 2023

PCR-based assays to detect human circulating DNA in mice demonstrate that human PTEGR2 assays are specific (A) and sensitive (B). Human-derived DNA could be detected in plasma of PDX (C).
Supplementary Table 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Authors: Ang Joo Ern , Pal Akos , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de haven Brandon Alexis , Revell Victoria L. , Skene Debra J. , Venturi Miro , Rueger Ruediger , Meresse Valerie , Eccles Suzanne A. , de Bono Johann S. , Kaye Stanley B. , Workman Paul , Banerji Udai , Raynaud Florence I.
Published: April 2023

Time of day variation in metabolites in healthy volunteers and in patients treated with the MEK inhibitor.
Supplementary S1 from Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo
Authors: Chen Zhen , Chen Yifan , Xu Meng , Chen Likun , Zhang Xu , To Kenneth Kin Wah , Zhao Hongyun , Wang Fang , Xia Zhongjun , Chen Xiaoqin , Fu Liwu
Published: April 2023

Figure S1. The express type of EGFR in S1, S1-MI-80, KB and KBv200 cell lines
Supplementary Materials and Methods and Supplementary Figures 1-6 from The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells
Authors: Delgado-Goni Teresa , Miniotis Maria Falck , Wantuch Slawomir , Parkes Harold G. , Marais Richard , Workman Paul , Leach Martin O. , Beloueche-Babari Mounia
Published: April 2023

Supplementary material and methods: -Western blotting -Quantitative real-time PCR (qRT-PCR) -Reactive oxygen species (ROS) production assay -NMR metabolic analyses of cells -NMR data acquisition and processing -Measurements of ADP/ATP ratios Supplementary Figures: -Figure S1: Cell proliferation is not significantly different using 25 mM or 5 mM glucose medium after 24h or 48h of treatment. -Figrue S2: BRAF mutant cells maintain their bioenergetics level under BRAF inhibition. -Figure S3: BRAF mutant WM266.4 cells show increased ROS levels under BRAF inhibition. -Figure S4: Changes in cell counts in WM266.4 and SKMEL28 control and treated samples in the 4 nutrient-restricted conditions. -Figure S5: Changes in cell cycle distribution in control and vemurafenib-treated WM266.4 cell samples in the 4 different nutrient conditions. -Figure S6: Cell lipid content detection by 1H NMR.
Supplemental Figure S5 from Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Jeffrey Scott C. , Hunter Joshua H. , Doronina Svetlana O. , Okeley Nicole M. , Miyamoto Jamie B. , Anderson Martha E. , Stone Ivan J. , Ulrich Michelle L. , Simmons Jessica K. , McKinney Erica E. , Senter Peter D. , Lyon Robert P.
Published: April 2023

Hematology paramters
Supplemental Figure S2 from Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Authors: Burke Patrick J. , Hamilton Joseph Z. , Jeffrey Scott C. , Hunter Joshua H. , Doronina Svetlana O. , Okeley Nicole M. , Miyamoto Jamie B. , Anderson Martha E. , Stone Ivan J. , Ulrich Michelle L. , Simmons Jessica K. , McKinney Erica E. , Senter Peter D. , Lyon Robert P.
Published: April 2023

ADC plasma stability
Supplemental Table S6 from Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Authors: Campbell Carly T. , Haladyna Jessica N. , Drubin David A. , Thomson Ty M. , Maria Michael J. , Yamauchi Taylor , Waters Nigel J. , Olhava Edward J. , Pollock Roy M. , Smith Jesse J. , Copeland Robert A. , Blakemore Stephen J. , Bernt Kathrin M. , Daigle Scott R.
Published: April 2023

Contains all pathways altered in NOMO-1 resistance identified by analysis with KEGG, GO - Biological Process, and MSigDB databases.
Supplemental Table S4 from Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Authors: Campbell Carly T. , Haladyna Jessica N. , Drubin David A. , Thomson Ty M. , Maria Michael J. , Yamauchi Taylor , Waters Nigel J. , Olhava Edward J. , Pollock Roy M. , Smith Jesse J. , Copeland Robert A. , Blakemore Stephen J. , Bernt Kathrin M. , Daigle Scott R.
Published: April 2023

Contains the mechanism footprint gene list referenced by supplemental Table S3.
Supplementary Figure S3 from PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Authors: Packer Leisl M. , Geng Xinyan , Bonazzi Vanessa F. , Ju Robert J. , Mahon Clare E. , Cummings Margaret C. , Stephenson Sally-Anne , Pollock Pamela M.
Published: April 2023

Figure S3. Inhibition of FGFR and PI3K pathways by BGJ398, GDC-0941 BYL719 and BKM120 in MFE296 cells.
Supplementary Table 3 from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Authors: Emdal Kristina B. , Dittmann Antje , Reddy Raven J. , Lescarbeau Rebecca S. , Moores Sheri L. , Laquerre Sylvie , White Forest M.
Published: April 2023

Summary of data from drug resistance evaluation
Supplementary Material and Method, Supplementary Tables 1-2, and Figure Legends from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Supplementary Table 1: IC20 and IC50 values of ARQ 092 and sorafenib in Hep3B, Huh-7, HepG2, PLC/PRF/5 and HR4 cell lines after 48h of exposure; Supplementary Table 2: List of significantly different phospho-kinases from ARQ 092 treated rats compared to control group.
Figure S4 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Immunohistochemistry
Figure S3 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Velocity and invasion
Figure S2 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Migration
Figure S1 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

(A) FACS data for UACC-62 cell line following 200nM and 2000nM treatment with BVD-523 for 24 hours. (B) Percentage of MIAPaCa2 cells in G1, S, or G2 phase of the cell cycle following 0, 24 and 48 hours of 5μM BVD-523 treatment.
Supplementary Table S3 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Authors: Uitdehaag Joost C.M. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Willemsen-Seegers Nicole , de Vetter Judith R.F. , Dylus Jelle , van Doornmalen Antoon M. , Kooijman Jeffrey , Sawa Masaaki , van Gerwen Suzanne J.C. , de Man Jos , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

All IC50 values, reproducibility, other metrics, all correlations, ibrutinib biochemical IC50
Supplementary figures S1-9 from Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma
Authors: Ao Jian-Yang , Zhu Xiao-Dong , Chai Zong-Tao , Cai Hao , Zhang Yuan-Yuan , Zhang Ke-Zhi , Kong Ling-Qun , Zhang Ning , Ye Bo-Gen , Ma De-Ning , Sun Hui-Chuan
Published: April 2023

Figure S1. Microscope pictures, and CSF1R expression of M(CSF1) cells and M(CSF2) cells. Figure S2. Microarray and qRT-PCR difference between M(LPS IFNÃƒÅ½Ã,Â³)/M(IL4), and between M(CSF1)/M(CSF2) cells. Figure S3. Effect of PLX3397 on the population doubling curve of the hepatoma cell lines, HUVEC, LX2, M(CSF2) cells, and T cells. Figure S4. Microvessel density expression in the vehicle and PLX3397 groups. Figure S5. TAMs of PLX3397-treated tumors were promoted towards a M1 phenotype. Figure S6. CSF2 is a key factor in between M(CSF1) and M(CSF2) cells. Figure S7. The tumor immunity environment was ameliorated after CSF1R inhibition in the allograft hepatoma model. Figure S8. CSF1R inhibition retarded HepG2 and HCCLM3 mice orthotopic xenograft growth. Figure S9. TAMs of PLX3397-treated tumors were promoted towards a M1 phenotype was also found in the xenografts after CSF1R inhibition.
Supplementary Tables S1-3 from Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma
Authors: Ao Jian-Yang , Zhu Xiao-Dong , Chai Zong-Tao , Cai Hao , Zhang Yuan-Yuan , Zhang Ke-Zhi , Kong Ling-Qun , Zhang Ning , Ye Bo-Gen , Ma De-Ning , Sun Hui-Chuan
Published: April 2023

Supplementary Table S1: Primer sequence of gene used for qPCR in mouse. Supplementary Table S2: Primer sequence of gene used for qPCR in human. Supplementary Table S3: List of antibodies used for immunohistochemical staining.
Supplemental data from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

Supplemental table 1. shRNA targeting sequences;Supplemental table 2. Primers for Q-PCR; Legends for 6 Supplemental Figures
Supplemental Figure S5 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

Gene expression in GSC20-SCR and GSC20-MSK1-sh cells was analyzed by microarray and top down-regulated genes were listed
Supplemental Figure S1 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

Chemical structure of DS7423
Supplemental Figures S1-S3 from CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
Authors: Däbritz J. Henry M. , Yu Yong , Milanovic Maja , Schönlein Martin , Rosenfeldt Mathias T. , Dörr Jan R. , Kaufmann Andreas M. , Dörken Bernd , Schmitt Clemens A.
Published: April 2023

This file contains supplemental figures 1-3. Figure S1 (related to Figure 1) depicts viability of EHEB, RC-K8 and SD-1 cells after Rituximab-based immunotherapy or chemotherapy. Figure S2 (related to Figure 2) shows CD20 expression levels of RC-K8 and SD-1 cells after ADR treatment as well as concentrations of senescence-associated cytokines IL-6 and IL-8 in RC-K8 media supernatants after combined immunochemotherapy. Figure S3 (related to Figure 3) illustrates target cell binding capability of Rituximab and cross-linker after NAC pre-treatment.
Supplementary figure 4 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 4. Caspase 3 assay
Supplementary figure 2 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 2. Cell viability evaluated by SRB assay after treatment with EC-70124 in DU145
Table S1, S2, S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Table S1. Patient background of each dataset. Table S2. Univariate Cox proportional hazards regression analysis in lung adenocarcinoma samples. Table S3. Univariate and multivariate Cox regression model of PROSPECT patients.
Supplementary Table 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Authors: Tao Le , Qiu Jianxin , Jiang Ming , Song Wenbin , Yeh Shuyuan , Yu Hong , Zang Lijuan , Xia Shujie , Chang Chawnshang
Published: April 2023

Pearson's correlation analysis of key genes in our pathway according to BLCA data set
Figure S1 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S1. Phase-contrast images of parental and acquired-resistance cells. Three acquired-resistance cells showed morphological changes to spindle shapes compared to parental cells.
Supplementary. Fig. S1 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

BS-181 could reverse the reduction of P-gp caused by triptolide
Figure S1 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

CDK10 knockdown in CRC cell lines. MIP101, RKO and HCT116 cells were transiently transfected with scramble siRNA or CDK10 siRNA for 72h followed by analysis of CDK10 expression by RT-PCR.
Table S1 and Figure S1-S4 from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
Authors: Dalal Kush , Che Meixia , Que Nanette S. , Sharma Aishwariya , Yang Rendong , Lallous Nada , Borgmann Hendrik , Ozistanbullu Deniz , Tse Ronnie , Ban Fuqiang , Li Huifang , Tam Kevin J. , Roshan-Moniri Mani , LeBlanc Eric , Gleave Martin E. , Gewirth Daniel T. , Dehm Scott M. , Cherkasov Artem , Rennie Paul S.
Published: April 2023

Supplementary Table S1: Cloning and RT-PCR primers used in this study; Supplementary Figure S1: Luciferase and cell viability experiments with MR49C and PC3 cells; Supplementary Figure S2: ITC control experiment between AR-DBD and dsDNA; Supplementary Figure S3: ChIP-PCR analysis; Supplementary Figure S4: Quality control for ChIP experiments
Supplemental Figure 3 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 3 shows impact of UNC2025 on cell viability.
Table S5 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

Differential CHiP with genes annotation specific for HCC827 Par and ZDR3
Table S2 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

Affinity Purification of EGFR, JUN, JNK, and FOS
Supplementary Figure S3 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

In vitro activity of S49076 and ionizing radiation combination
Supplementary Figure S2 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

Comparison of S49076 and PF-04217903 in vitro effects
Supporting Information from Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry
Authors: Houghton Jacob L. , Membreno Rosemery , Abdel-Atti Dalya , Cunanan Kristen M. , Carlin Sean , Scholz Wolfgang W. , Zanzonico Pat B. , Lewis Jason S. , Zeglis Brian M.
Published: April 2023

This document contains all supporting materials and methods as well as supplemental figures and tables.
Figure S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

In vitro molecular characterization of mAb inhibition of CLPTM1L signaling
Figure S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

CLPTM1L structural prediction
Supplementary Figure 2 from TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors
Authors: Abo Muthana Al , Sasanuma Hiroyuki , Liu Xiaojun , Rajapakse Vinodh N. , Huang Shar-yin , Kiselev Evgeny , Takeda Shunichi , Plunkett William , Pommier Yves
Published: April 2023

TDP1 expression in human cancer cells. TDP1 expression in the CCLE (A) or TCGA (B) databases. TDP1 messenger RNA (mRNA) expression was determined by Affymetrix's GeneChip array in CCLE (A) or RNA sequencing technology in TCGA (B). TDP1 expression is shown. Each dot represents a single cell line (A) or tumor specimen (B).
Supplementary Figure Legends from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
Authors: Guertin Amy D. , O'Neil Jennifer , Stoeck Alexander , Reddy Joseph A. , Cristescu Razvan , Haines Brian B. , Hinton Marlene C. , Dorton Ryan , Bloomfield Alicia , Nelson Melissa , Vetzel Marilynn , Lejnine Serguei , Nebozhyn Michael , Zhang Theresa , Loboda Andrey , Picard Kristen L. , Schmidt Emmett V. , Dussault Isabelle , Leamon Christopher P.
Published: April 2023

Legends for Supplementary Figures 1-4 and Supplementary Tables 1 & 2
Supplementary Materials from Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma
Authors: Cazzamalli Samuele , Dal Corso Alberto , Neri Dario
Published: April 2023

Herein we describe detailed synthetic procedures and characterization of the presented compounds (i.e., HPLC purity of final products, MS and NMR data, SPR assays), together with additional biological data (i.e., stability of 4a in the presence of Cathepsin B and CAIX, biodistribution in CAIX-negative lesions) and protocols (i.e., expression and purifycation of recombinant human CAIX).
supplementary figure S2 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

Figure S2 shows the DNA damage signalling after cell treatment with etoposide or F14512.
Supplementary Table 4 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

The IC50 values of BJ-1301, SU4312, and Î±-TOH on ROS production induced by VEGF and TPA
Supplementary Table 3 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

Comparison of ID50 of BJ-1301 and Î±-TOH in VEGF-induced angiogenesis in vivo
Supplementary Table2 from BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Authors: Wu Xinchao , Liu Dong , Tao Dan , Xiang Wei , Xiao Xingyuan , Wang Miao , Wang Liang , Luo Gang , Li Yawei , Zeng Fuqing , Jiang Guosong
Published: April 2023

CT values of GAPDH obtained from qPCR
Supplementary Figure3 from BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Authors: Wu Xinchao , Liu Dong , Tao Dan , Xiang Wei , Xiao Xingyuan , Wang Miao , Wang Liang , Luo Gang , Li Yawei , Zeng Fuqing , Jiang Guosong
Published: April 2023

Vector backbone of BRD4 expression plasmid
Supplementary methods and Supplementary results from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary methods and Supplementary results
Supplementary Table 3 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Table 3 Association of EZH2 and clinical factors of CRC patients
Figure S1 and S2 Legends from Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors
Authors: Porchia Bruna F.M.M. , Moreno Ana Carolina R. , Ramos Rodrigo N. , Diniz Mariana O. , de Andrade Laís Helena T.M. , Rosa Daniela S. , Barbuto José Alexandre M. , Boscardin Silvia B. , Ferreira Luís Carlos S.
Published: April 2023

Figure S1 and S2 Legends
Supplementary Figure 6 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 6. ROC analysis was performed to establish the potential cut-off values of MALAT1 (A) and miR-218 (B) in 46 primary CRC tissues for distinguishing responding and non-responding patients who had received standard FOLFOX treatment.
Supplementary Figure 2 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 2. Acquisition of oxaliplatin resistance induces EMT in HT29 cells. A. HT29 parental and OxR cells were treated with culture medium containing 2μM concentration of oxaliplatin, HT29 OxR cells are resistant to oxaliplatin while parental cells are sensitive to oxaliplatin treatment. B. The concentration -effect curve indicated that the IC50 value of oxaliplatin for HT29 OxR cells was 10.2 μM, while the IC50 of oxaliplatin on HT29 parental cells was 1.5 μM, which means that the HT29 OxR cells was 6.8 times the ability of oxaliplatin resistance of HT29 parental cells. C. Acquisition of oxaliplatin resistance induces morphologic changes consistent with EMT in HT29 cells. D. HT29 OxR cells have increased migratory and invasive capacity compared with HT29 parental cells. *, P<0.05 E. HT29 OxR cells exhibit molecular changes consistent with EMT such as decreased E-cadherin and increased Vimentin protein levels. F. HT29 OxR cells have reduced cell number at 48 and 72h by MTT assay. *, P<0.05 G. Cell cycle analysis showed an increase in the percentage of cells in G2 phase in HT29 OxR cells compared with parental cells. *, P<0.05.
Supplementary Table S1-S2 and Figure S1-S2 from Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Authors: Karkera Jayaprakash D. , Cardona Gabriela Martinez , Bell Katherine , Gaffney Dana , Portale Joseph C. , Santiago-Walker Ademi , Moy Christopher H. , King Peter , Sharp Michael , Bahleda Rastislav , Luo Feng R. , Alvarez John D. , Lorenzi Matthew V. , Platero Suso J.
Published: April 2023

Table S1. Frequencies of gene locus amplifications across tumor types; Table S2. Effect of FGFR inhibitors on growth of RK3E expressing FGFR2 and FGFR3 fusion constructs and RT-4 bladder cancer cell line; Figure S1. Chemical structure of JNJ-42756493; Figure S2. Western Blot confirming the overexpression of HA-tagged FGFR2 fusion genes
Supplementary Synthetic Methods from Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Authors: Yu Jia Xin , Craig Amanda J. , Duffy Mary E. , Villacorta-Martin Carlos , Miguela Verónica , Ruiz de Galarreta Marina , Scopton Alexander P. , Silber Lisa , Maldonado Andres Y. , Rialdi Alexander , Guccione Ernesto , Lujambio Amaia , Villanueva Augusto , Dar Arvin C.
Published: April 2023

Supplemental Synthetic Methods
Supplementary Data Figures 1-7 from Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Authors: Yu Jia Xin , Craig Amanda J. , Duffy Mary E. , Villacorta-Martin Carlos , Miguela Verónica , Ruiz de Galarreta Marina , Scopton Alexander P. , Silber Lisa , Maldonado Andres Y. , Rialdi Alexander , Guccione Ernesto , Lujambio Amaia , Villanueva Augusto , Dar Arvin C.
Published: April 2023

Supplementary Data Figures 1 shows PK data on AD80. Supplementary Data Figure 2 shows PCA analysis. Supplementary Data Figure 3 shows Gene Set Enrichment of HUH7 cells in response to AD80 and sorafenib. Supplementary Data Figure 4 shows western blot data. Supplementary Data Figure 5 shows representative purification gels of p38 isoforms used in the study. Supplementary Data Figure 6 shows a p38 sequence alignment. Supplementary Data Figure 7 shows rescue data.
Supplementary figure legends from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Authors: Wu Chuan Xing , Xu Aimin , Zhang Cathy C. , Olson Peter , Chen Lin , Lee Terence K. , Cheung Tan To , Lo Chung Mau , Wang Xiao Qi
Published: April 2023

Supplementary figure legends
Supplementary Tables from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Authors: Wu Chuan Xing , Xu Aimin , Zhang Cathy C. , Olson Peter , Chen Lin , Lee Terence K. , Cheung Tan To , Lo Chung Mau , Wang Xiao Qi
Published: April 2023

Table S1: Primer sequences; Table S2. The association of clinicopathological parameters or Notch1 expression with HCC overall survival and disease-free survival using univariate and multivariate analysis
Supplemental Figures S1-S14 from Loss of NF2 Induces TGFβ Receptor 1–mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome
Authors: Cho Jung-Hyun , Oh Ah-Young , Park Soyoung , Kang So-mi , Yoon Min-Ho , Woo Tae-Gyun , Hong Shin-Deok , Hwang Jihwan , Ha Nam-Chul , Lee Ho-Young , Park Bum-Joon
Published: April 2023

Supplementary Figure S1. Loss of NF2 protects mechanical stress-induced cell death. Supplementary Figure S2. TβR1 is sensor of physical stimulation. Supplementary Figure S3. TβR1 kinase activity is required for RKIP and NF2 suppression. Supplementary Figure S4. Loss of NF2 induces unbalanced TβR1 and TβR2 expression. Supplementary Figure S5. TβR1-mediated oncogenic signal such as invasion can be blocked by TβR2. Supplementary Figure S6. NF2 blocks the binding between RKIP and TβR1. Supplementary Figure S7. TβR1 phosphorylates RKIP. Supplementary Figure S8. The effect of TβR1 kinase inhibitors on NF2-deficient cells. Supplementary Figure S9. The effect of several kinds of selective TβR1 inhibitors. Supplementary Figure S10. Gene expression analysis. Supplementary Figure S11. TEW7197 induces HEI-193 differentiation into Schwann cell. Supplementary Figure S12. Histological analysis in NF2 syndrome model mouse. Supplementary Figure S13. Mouse phenotype. Supplementary Figure S14. Effect of TEW7197 treatment on the primary tumor cells isolated from vehicle-treated NF2 syndrome model mouse.
Supplementary Table S4 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Validation of predictive response biomarkers
Supplementary Figure S1 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Workflow for filtering cell line genomic data
Table S5 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Ex vivo biodistribution of 68Ga-NOTA-sdAb 9077, 9079 and non-target control sdAb (68Ga-NOTA-ctrl sdAb) at 1.5 h p.i., in hCD20 B16 tumor mouse model. Results are presented as mean % IA/g {plus minus} SD (n = 3 per sdAb).
Table S3 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Ex vivo biodistribution of 14 anti-hCD20 sdAbs and non-target control sdAb (ctrl sdAb), radiolabeled with 99mTc, in hCD20 B16 tumor mouse models. Results are expressed as % IA/g {plus minus} SD (n = 3 per SdAb). T/M: Tumor-to-Muscle ratio; T/B: Tumor-to-Blood ratio.
Figure S2 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Affinity of 177Lu-DTPA-sdAb 9077 and 177Lu-DTPA- sdAb 9079 towards hCD20 receptor was calculated by incubating serial dilutions with hCD20pos B16 cells. The calculated KD values of 22.7 {plus minus} 2.7 nM and 28.5 {plus minus} 2.2 nM for 177Lu-DTPA-anti-hCD20 sdAbs 9077 and 9079, respectively, were obtained. B) Stability of 177Lu-DTPA-sdAb 9077 and 177Lu-DTPA-sdAb 9079 in human serum at 37 {degree sign}C. Both 177Lu-radiolabeled anti-hCD20 sdAbs showed > 91 % intact complexes after 144 h incubation.
Supplementary Table S2 from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers
Authors: Talwelkar Sarang S. , Nagaraj Ashwini S. , Devlin Jennifer R. , Hemmes Annabrita , Potdar Swapnil , Kiss Elina A. , Saharinen Pipsa , Salmenkivi Kaisa , Mäyränpää Mikko I. , Wennerberg Krister , Verschuren Emmy W.
Published: April 2023

Table_S2
Supplementary Data from Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers
Authors: Talwelkar Sarang S. , Nagaraj Ashwini S. , Devlin Jennifer R. , Hemmes Annabrita , Potdar Swapnil , Kiss Elina A. , Saharinen Pipsa , Salmenkivi Kaisa , Mäyränpää Mikko I. , Wennerberg Krister , Verschuren Emmy W.
Published: April 2023

Supplementary text and figures
Supplementary Materials and Methods, Tables S1-S2, and Figures S1-S6 from Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Authors: Magnaghi Paola , Salom Barbara , Cozzi Liviana , Amboldi Nadia , Ballinari Dario , Tamborini Elena , Gasparri Fabio , Montagnoli Alessia , Raddrizzani Laura , Somaschini Alessio , Bosotti Roberta , Orrenius Christian , Bozzi Fabio , Pilotti Silvana , Galvani Arturo , Sommer Josh , Stacchiotti Silvia , Isacchi Antonella
Published: April 2023

Supplementary Table S1: Short Tandem Repeat (STR) fingerprinting; Supplementary Table S2: Anti-proliferative activity of MET and PDGFR inhibitors in chordoma cell lines; Supplementary Figure S1: Live-cell kinetic analysis of afatinib activity in U-CH1 cell line; Supplementary Figure S2: Effect of dacomitinib on EGFR and brachyury proteins; Supplementary Figure S3: Effect of EGFR and brachyury siRNA on U-CH1 cell viability and target proteins levels; Supplementary Figure S4: Analysis of the mechanism of afatinib-induced EGFR and brachyury down-modulation in U-CH1 chordoma cell line; Supplementary Figure S5: EGFR localization and phosphorylation in the different chordoma cell lines; Supplementary Figure S6: Short term pharmaco-dynamic response to afatinib.
Supplementary figure and table legends from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Supplementary figure and table legends
Supplementary Figure S5 from Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Authors: Islam Waliul , Fang Jun , Imamura Takahisa , Etrych Tomas , Subr Vladimir , Ulbrich Karel , Maeda Hiroshi
Published: April 2023

Supplementary Figure S5 shows change of tumor blood flow by the treatment of each EPR-effect enhancer.
Supplementary Figure S4 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Heatmap of normalized AUC including BxPC-3
Supplementary Figure S3 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Single agent drug sensitivities by cell line and category
Supplementary Figure S1 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Heatmap of non-normalized AUC and cell lines
Supplementary Table 2 from Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
Authors: MacDonald Amanda , Priess Michelle , Curran Jennifer , Guess Jamey , Farutin Victor , Oosterom Ilse , Chu Chia Lin , Cochran Edward , Zhang Lynn , Getchell Kristen , Lolkema Martijn , Schultes Birgit C. , Krause Silva
Published: April 2023

Supplementary Table 2 lists GO Categories significantly altered by necuparanib treatment, assigned to cancer-driving pathways
Supplemental Figure 3 from Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
Authors: MacDonald Amanda , Priess Michelle , Curran Jennifer , Guess Jamey , Farutin Victor , Oosterom Ilse , Chu Chia Lin , Cochran Edward , Zhang Lynn , Getchell Kristen , Lolkema Martijn , Schultes Birgit C. , Krause Silva
Published: April 2023

Supplemental Figure 3 shows MMP1 and MMP7 protein levels were unchanged in the plasma of patients.
Supplementary Figure 3 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Authors: Chen Luxi , Yuan Yi , Kar Shreya , Kanchi Madhu M. , Arora Suruchi , Kim Ji E. , Koh Pei F. , Yousef Einas , Samy Ramar P. , Shanmugam Muthu K. , Tan Tuan Z. , Shin Sung W. , Arfuso Frank , Shen Han M. , Yang Henry , Goh Boon C. , Park Joo I. , Gaboury Louis , Lobie Peter E. , Sethi Gautam , Lim Lina H.K. , Kumar Alan P.
Published: April 2023

Supplementary Figure 3: PPARγ induced expression of ANXA1 and cell death is abrogated in TNBC cells with pre-incubation of a PPARγ-specific antagonist or use of a dominant negative derivative of PPARγ.
Supplementary Table S1 and Supplementary Figures S1-S6 from Cell Death Induced by Cationic Amphiphilic Drugs Depends on Lysosomal Ca2+ Release and Cyclic AMP
Authors: Anand Atul , Liu Bin , Dicroce Giacobini Jano , Maeda Kenji , Rohde Mikkel , Jäättelä Marja
Published: April 2023

Table S1 list the resources used. Figures S1-S5 supplement the data presented in figures 1-6 and Figure S6 provides a schematic presentation of the proposed CAD signaling pathway.
Supplementary Figures from The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer
Authors: Tran Linh N.K. , Kichenadasse Ganessan , Butler Lisa M. , Centenera Margaret M. , Morel Katherine L. , Ormsby Rebecca J. , Michael Michael Z. , Lower Karen M. , Sykes Pamela J.
Published: April 2023

S1: Comparison of the Incucyte FLR and Operetta High Content Imaging System for detection of apoptosis in PC-3 cells induced by Paclitaxel. S2: Nuclear fragmentation index of PC-3 cells in the presence and absence of ectopically expressed p53 in response to MET and VPA. S3: p53 knock-down in LNCaP cells using siRNA. S4: Efficiency of GFP-p53 and GFP-only plasmid transfection in PC-3 cells. S5: Apoptosis in PC-3 cells in response to MET and VPA in the presence and absence of Enzalutamide.
Supplementary Figure Legends from The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer
Authors: Tran Linh N.K. , Kichenadasse Ganessan , Butler Lisa M. , Centenera Margaret M. , Morel Katherine L. , Ormsby Rebecca J. , Michael Michael Z. , Lower Karen M. , Sykes Pamela J.
Published: April 2023

Legends of supplementary Figure S1, S2, S3, S4, and S5.
Table S3 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Table 3 shows the effects of lenvatinib and sorafenib on the production of angiogenesis-related cytokines from ATC cells.
Figure S5 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

In vivo evaluation of DON administration.
Figure S3 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

HBP inhibition affects phosphorylation of target protein, expression of transcription factors and cause minor change in cellular metabolism.
Figure S4 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 4 shows EGFP-Eluc expression did not affect the sensitivity of OCUT-1C cells to lenvatinib or sorafenib.
Figure S3 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 3 shows the activation of cell cycle-, and apoptosis-related proteins treated with lenvatinib or sorafenib in OCUT-1C and OCUT-2 cell subcutaneous tumors.